V

Viking Therapeutics
D

VKTX

24.240
USD
-1.46
(-5.68%)
Market Closed
Volume
213,588
EPS
-2
Div Yield
-
P/E
-24
Market Cap
2,720,886,890
Related Instruments
A
ABUS
0.01300
(0.37%)
3.51500 USD
ALNY
ALNY
-4.62
(-1.73%)
262.41 USD
A
ARWR
-0.610
(-4.81%)
12.070 USD
C
CRBP
-0.28000
(-5.37%)
4.93000 USD
MRNA
MRNA
-2.020
(-7.29%)
25.700 USD
R
RGLS
-0.16500
(-8.33%)
1.81500 USD
V
VKTX
-1.460
(-5.68%)
24.240 USD
More
News

Title: Viking Therapeutics

Sector: Healthcare
Industry: Biotechnology
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.